biostudies-literatureUnknown41(36)Vergote I<h4>Purpose</h4>Tissue factor is highly expressed in cervical carcinoma and can be targeted by tisotumab vedotin (TV), an antibody-drug conjugate. This phase Ib/II study evaluated TV in combination with bevacizumab, pembrolizumab, or carboplatin for recurrent or metastatic cervical cancer (r/mCC).<h4>Methods</h4>This open-label, multicenter study (ClinicalTrials.gov identifier: NCT03786081) included dose-escalation arms that assessed dose-limiting toxicities (DLTs) and identified the recommended phase II dose (RP2D) of TV in combination with bevacizumab (arm A), pembrolizumab (arm B), or carboplatin (arm C). The dose-expansion arms evaluated TV antitumor activity and safety at RP2D in combination with carboplatin as first-line (1L) treatment (arm D) or with pembrolizumab as 1L (arm E) or sJournal of clinical oncology : official journal of the American Society of Clinical Oncology5536-5549https://www.ebi.ac.uk/biostudies/studies/S-EPMC10730069biostudies-literatureTisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study.PMC10730069Denys HGSadozye AMadsen KGhamande SCollins DCCibula DChisamore MJScambia GMondrup Andreassen CGort EVan Nieuwenhuysen EBaurain JFBanerjee SMonk BJBoere IAOttevanger NLorusso DEaton LVergote IRandall LMO'Cearbhaill RESoumaoro IWestermann AKose FMathews CAGennigens CZikan MForget FTewari KSJackson ALViana Nicacio LfalseTisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study.<h4>Purpose</h4>Tissue factor is highly expressed in cervical carcinoma and can be targeted by tisotumab vedotin (TV), an antibody-drug conjugate. This phase Ib/II study evaluated TV in combination with bevacizumab, pembrolizumab, or carboplatin for recurrent or metastatic cervical cancer (r/mCC).<h4>Methods</h4>This open-label, multicenter study (ClinicalTrials.gov identifier: NCT03786081) included dose-escalation arms that assessed dose-limiting toxicities (DLTs) and identified the recommended phase II dose (RP2D) of TV in combination with bevacizumab (arm A), pembrolizumab (arm B), or carboplatin (arm C). The dose-expansion arms evaluated TV antitumor activity and safety at RP2D in combination with carboplatin as first-line (1L) treatment (arm D) or with pembrolizumab as 1L (arm E) or s2023-01-01T00:00:00Z2023 Dec2025-04-26T20:33:43.021Z2025-04-06T16:26:41.744ZS-EPMC107300693765165510.1200/JCO.23.00720